Table of Contents
Scholarly Research Exchange
Volume 2008, Article ID 467264, 5 pages
http://dx.doi.org/10.3814/2008/467264
Clinical Study

Upregulation of Monocyte Chemoattractant Protein-1 (MCP-1) in Early Diabetic Nephropathy in Patients with Type-1 Diabetes Mellitus

1Department of Nephrology, Faculty of Medicine, Tanta University, Gharbia, Egypt
2Department of Internal Medicine, Faculty of Medicine, Tanta University, Gharbia, Egypt
3Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
4Department of Clinical Pathology, Faculty of Medicine, Alazhar University, Cairo, Egypt

Received 25 June 2008; Accepted 10 September 2008

Copyright © 2008 Eid El-Shafey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Diabetes Association, “Standards of medical care in diabetes—2007,” Diabetes Care, vol. 30, pp. S4–S41, 2007. View at Publisher · View at Google Scholar · View at PubMed
  2. H. H. Parving, R. Osterby, P. W. Anderson, and W. A. Hsueh, “Diabetic nephropathy,” in The Kidney, B. M. Brenner, Ed., pp. 1864–1892, WB Saunders, Philadelphia, Pa, USA, 5th edition, 1996. View at Google Scholar
  3. C. E. Mogensen, “Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas,” Diabetologia, vol. 42, no. 3, pp. 263–285, 1999. View at Publisher · View at Google Scholar
  4. M. E. Cooper, R. E. Gilbert, and G. Jerums, “Diabetic vascular complications,” Clinical and Experimental Pharmacology and Physiology, vol. 24, no. 9-10, pp. 770–775, 1997. View at Publisher · View at Google Scholar
  5. M. E. Cooper, “Pathogenesis, prevention, and treatment of diabetic nephropathy,” The Lancet, vol. 352, no. 9123, pp. 213–219, 1998. View at Publisher · View at Google Scholar
  6. T. Wada, K. Furuichi, N. Sakai et al., “Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy,” Kidney International, vol. 58, no. 4, pp. 1492–1499, 2000. View at Publisher · View at Google Scholar · View at PubMed
  7. F. Cipollone, M. Marini, M. Fazia et al., “Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 327–334, 2001. View at Google Scholar
  8. T. Wada, H. Yokoyama, K. Furuichi et al., “Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1),” The FASEB Journal, vol. 10, no. 12, pp. 1418–1425, 1996. View at Google Scholar
  9. W. W. Tang, S. Yin, A. J. Wittwer, and M. Qi, “Chemokine gene expression in anti-glomerular basement membrane antibody glomerulonephritis,” American Journal of Physiology, vol. 269, no. 3, pp. F323–F330, 1995. View at Google Scholar
  10. Yu. Natori, M. Sekiguchi, Z. Ou, and Ya. Natori, “Gene expression of CC chemokines in experimental crescentic glomerulonephritis (CGN),” Clinical & Experimental Immunology, vol. 109, no. 1, pp. 143–148, 1997. View at Publisher · View at Google Scholar
  11. T. Wada, K. Furuichi, C. Segawa-Takaeda et al., “MIP-1α and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis,” Kidney International, vol. 56, no. 3, pp. 995–1003, 1999. View at Publisher · View at Google Scholar · View at PubMed
  12. T. Wada, H. Yokoyama, S.-B. Su et al., “Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis,” Kidney International, vol. 49, no. 3, pp. 761–767, 1996. View at Publisher · View at Google Scholar
  13. H. Yokoyama, T. Wada, K. Furuichi et al., “Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy,” Journal of Leukocyte Biology, vol. 63, no. 4, pp. 493–499, 1998. View at Google Scholar
  14. I.-S. Park, H. Kiyomoto, S. L. Abboud, and H. E. Abboud, “Expression of transforming growth factor-β and type IV collagen in early streptozotocin-induced diabetes,” Diabetes, vol. 46, no. 3, pp. 473–480, 1997. View at Publisher · View at Google Scholar
  15. T. Furuta, T. Saito, T. Ootaka et al., “The role of macrophages in diabetic glomerulosclerosis,” American Journal of Kidney Diseases, vol. 21, no. 5, pp. 480–485, 1993. View at Google Scholar
  16. B. A. Young, R. J. Johnson, C. E. Alpers et al., “Cellular events in the evolution of experimental diabetic nephropathy,” Kidney International, vol. 47, no. 3, pp. 935–944, 1995. View at Publisher · View at Google Scholar
  17. R. A. K. Stahl, F. Thaiss, M. Disser, U. Helmchen, K. Hora, and D. Schlöndorff, “Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis,” Kidney International, vol. 44, no. 5, pp. 1036–1047, 1993. View at Publisher · View at Google Scholar
  18. C.-G. Ihm, “Monocyte chemotactic peptide-1 in diabetic nephropathy,” Kidney International. Supplement, vol. 60, pp. S20–S22, 1997. View at Google Scholar
  19. P. Hovind, L. Tarnow, P. Rossing et al., “Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study,” British Medical Journal, vol. 328, no. 7448, pp. 1105–1108, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. M. Murussi, P. Baglio, J. L. Gross, and S. P. Silveiro, “Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study,” Diabetes Care, vol. 25, no. 6, pp. 1101–1103, 2002. View at Publisher · View at Google Scholar
  21. B. A. Perkins, L. H. Ficociello, K. H. Silva, D. M. Finkelstein, J. H. Warram, and A. S. Krolewski, “Regression of microalbuminuria in type 1 diabetes,” The New England Journal of Medicine, vol. 348, no. 23, pp. 2285–2293, 2003. View at Publisher · View at Google Scholar · View at PubMed
  22. F. Chiarelli, F. Cipollone, A. Mohn et al., “Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes,” Diabetes Care, vol. 25, no. 10, pp. 1829–1834, 2002. View at Publisher · View at Google Scholar
  23. F. Cipollone, F. Chiarelli, A. Iezzi et al., “Relationship between reduced BCL-2 expression in circulating mononuclear cells and early nephropathy in type 1 diabetes,” International Journal of Immunopathology and Pharmacology, vol. 18, no. 4, pp. 625–635, 2005. View at Google Scholar
  24. N. Banba, T. Nakamura, M. Matsumura, H. Kuroda, Y. Hattori, and K. Kasai, “Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy,” Kidney International, vol. 58, no. 2, pp. 684–690, 2000. View at Publisher · View at Google Scholar · View at PubMed
  25. S. Kiyici, E. Erturk, F. Budak et al., “Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy,” Archives of Medical Research, vol. 37, no. 8, pp. 998–1003, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. P. Gæde, H. E. Poulsen, H.-H. Parving, and O. Pedersen, “Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients,” Diabetic Medicine, vol. 18, no. 9, pp. 756–760, 2001. View at Publisher · View at Google Scholar
  27. Y. Ishikawa, H. Sugiyama, E. Stylianou, and M. Kitamura, “Bioflavonoid quercetin inhibits interleukin-1-induced transcriptional expression of monocyte chemoattractant protein-1 in glomerular cells via suppression of nuclear factor-κB,” Journal of the American Society of Nephrology, vol. 10, no. 11, pp. 2290–2296, 1999. View at Google Scholar
  28. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, “Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy,” The Lancet, vol. 355, no. 9200, pp. 253–259, 2000. View at Publisher · View at Google Scholar